Magnetresonanztomographie in der Diagnostik des Gallensteinleidens:Gibt die Wahl geringerer Schichtdicken ein besseres Ergebnis im Hinblick auf die Diagnosefindung?

Die Diagnostik des Gallenstenleidens muss im Zeitalter des DRG-Systems möglichst effizient gestaltet werden. Diese Studie prüft die Wertigkeit von 4-mm- und 7-mm-Schichtdicken im MR mittels SSL-FB- und SSL-SPIR- sowie MRCP-Sequenzen im Vergleich. Hierbei wurden 93 Patienten (26 m : 67 w) mit Cholezystolihiasis und 11 Patienten (4 m : 7 w) mit Choledocholithiasis eingeschlossen und mit postoperativen und alternativen Untersuchungsbefunden (ERCP) verglichen. Alle Untersuchungsergebnisse waren absolut identisch, so dass kein Vorteil einer geringeren Schichtdicke im MR zur Diagnosefindung nachgewiesen werden konnte. Insbesondere bei der Fragestellung einer Cholezystolithiasis reicht laut dieser Untersuchung eine 7-mm-Schichtdicke aus

Closed-Loop supply chains in circular economy business models

With the emergence of the circular economy (CE) approach into business models, there is need for deeper understanding of resource loops activities and how current supply chains can support the development of emerging CE business models. However, there is still limited research addressing the conceptualization of closed loops in the supply chain literature. This work addresses this research gap and proposes a typology for closed loops that is independent from the type of product under concern. Our findings suggest that there are two types of closed-loop supply chains in circular business models. Further work is envisaged to understand how companies can effectively develop their closed-loop supply chains as part of their transformation towards a more circular business model

In-hospital and 6-month outcomes in patients with COVID-19 supported with extracorporeal membrane oxygenation (EuroECMO-COVID): a multicentre, prospective observational study

Background: Extracorporeal membrane oxygenation (ECMO) has been widely used in patients with COVID-19, but uncertainty remains about the determinants of in-hospital mortality and data on post-discharge outcomes are scarce. The aims of this study were to investigate the variables associated with in-hospital outcomes in patients who received ECMO during the first wave of COVID-19 and to describe the status of patients 6 months after ECMO initiation. Methods: EuroECMO-COVID is a prospective, multicentre, observational study developed by the European Extracorporeal Life Support Organization. This study was based on data from patients aged 16 years or older who received ECMO support for refractory COVID-19 during the first wave of the pandemic—from March 1 to Sept 13, 2020—at 133 centres in 21 countries. In-hospital mortality and mortality 6 months after ECMO initiation were the primary outcomes. Mixed-Cox proportional hazards models were used to investigate associations between patient and management-related variables (eg, patient demographics, comorbidities, pre-ECMO status, and ECMO characteristics and complications) and in-hospital deaths. Survival status at 6 months was established through patient contact or institutional charts review. This study is registered with ClinicalTrials.gov, NCT04366921, and is ongoing. Findings: Between March 1 and Sept 13, 2020, 1215 patients (942 [78%] men and 267 [22%] women; median age 53 years [IQR 46–60]) were included in the study. Median ECMO duration was 15 days (IQR 8–27). 602 (50%) of 1215 patients died in hospital, and 852 (74%) patients had at least one complication. Multiorgan failure was the leading cause of death (192 [36%] of 528 patients who died with available data). In mixed-Cox analyses, age of 60 years or older, use of inotropes and vasopressors before ECMO initiation, chronic renal failure, and time from intubation to ECMO initiation of 4 days or more were associated with higher in-hospital mortality. 613 patients did not die in hospital, and 547 (95%) of 577 patients for whom data were available were alive at 6 months. 102 (24%) of 431 patients had returned to full-time work at 6 months, and 57 (13%) of 428 patients had returned to part-time work. At 6 months, respiratory rehabilitation was required in 88 (17%) of 522 patients with available data, and the most common residual symptoms included dyspnoea (185 [35%] of 523 patients) and cardiac (52 [10%] of 514 patients) or neurocognitive (66 [13%] of 512 patients) symptoms. Interpretation: Patient's age, timing of cannulation (<4 days vs ≥4 days from intubation), and use of inotropes and vasopressors are essential factors to consider when analysing the outcomes of patients receiving ECMO for COVID-19. Despite post-discharge survival being favourable, persisting long-term symptoms suggest that dedicated post-ECMO follow-up programmes are required. Funding: None